Rockwell Medical (RMTI) FDA Triferic Approval 'De-Risk' the Story, Summer Street Says
Tweet Send to a Friend
Summer Street analyst Jim Molloy reiterated a Buy rating and $25 price target on Rockwell Medical Technologies (NASDAQ: RMTI) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
